Read this manager's filing book
Disclosed positions
GSK plc: source evidence dated 2026-08-14T03:59:59.999Z.
- Issuer
- CRISPR THERAPEUTICS AG
- Ticker
- CRSP
- Class
- NAMEN AKT
- Reported value
- $175,652,997
- Reported amount
- 3,220,627
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001999371-26-017873Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| CRISPR THERAPEUTICS AG | CRSP | NAMEN AKT | $175,652,997 | 3,220,627 | SH | None |
| WAVE LIFE SCIENCES LTD | WVE | SHS | $106,007,465 | 18,245,691 | SH | None |
| VIR BIOTECHNOLOGY INC | VIR | COM | $87,134,221 | 8,550,954 | SH | None |
| BIONTECH SE | BNTX | SPONSORED ADS | $82,798,123 | 889,824 | SH | None |
| IDEAYA BIOSCIENCES INC | IDYA | COM | $49,693,321 | 1,333,333 | SH | None |
| CYTOKINETICS INC | CYTK | COM NEW | $29,001,573 | 340,434 | SH | None |
| LYELL IMMUNOPHARMA INC | LYEL | COM NEW | $21,252,859 | 1,512,659 | SH | None |
| SPERO THERAPEUTICS INC | SPRO | COM | $20,311,239 | 9,190,606 | SH | None |
| NKARTA INC | NKTX | COM | $8,916,572 | 3,150,732 | SH | None |
| FULCRUM THERAPEUTICS INC | FULC | COM | $6,535,713 | 1,785,714 | SH | None |
| BICYCLE THERAPEUTICS PLC | BCYC | SPONSORED ADS | $6,485,339 | 1,529,561 | SH | None |
| CVRX INC | CVRX | COM | $5,178,977 | 1,007,583 | SH | None |
| REGENXBIO INC | RGNX | COM | $3,252,043 | 271,456 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 0 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.